Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) today announced that expanding clinical applications for its medical devices and new products contributed to record operating revenue of NZ$516.7 million for the year ended 31 March 2012.
The company reported net profit after tax of NZ$64.1 million, compared to NZ$52.5 million for the prior year. The prior year result included one-off non-cash deferred tax charges of NZ$11.5 million.
In constant currency terms, and excluding the prior year deferred tax charges, the company’s net profit after tax grew 23%, primarily as a result of revenue growth, disciplined control of expenses and other efficiencies.
The company derived approximately 52% of its operating revenue in US dollars. In US dollars, the company’s respiratory and acute care product group (RAC) operating revenue increased by 18% and obstructive sleep apnea (OSA) product group revenue increased by 7%, over the prior year.
“Strong growth in our RAC product group was driven by rapidly growing acceptance of our products which are used in applications outside of intensive care ventilation, with operating revenue from consumables used in those new applications increasing 24% in constant currency terms”, commented Fisher & Paykel Healthcare’s CEO, Mr Michael Daniell.
“In our OSA product group, constant currency flow generator revenue growth of 18% over the prior year reflected strong growth from our ICON range. Mask revenue reduced 4% in constant currency terms, but began to improve late in the year, following the launch of the first of a number of innovative new masks”.
The company’s directors have approved a final dividend for the financial year ended 31 March 2012 of 7.0 NZ cents per ordinary share (2011: 7.0 cents), carrying full imputation credit based on a tax rate of 28%. For New Zealand resident shareholders that results in a gross dividend of 9.722 cents per ordinary share. Eligible non-resident shareholders will receive a supplementary dividend of 1.235 NZ cents per ordinary share. The final dividend will be paid on 6 July 2012, with a record date of 22 June 2012, and ex-dividend dates of 18 June 2012 for the ASX and 20 June 2012 for the NZSX.
The company offers a dividend reinvestment plan (DRP), under which eligible shareholders may elect to reinvest all or part of their cash dividends in additional shares. A 3% discount will be applied when determining the price per share of shares issued under the DRP and will be applied in respect of the 2012 final dividend and future dividends, until such time as the directors determine otherwise.
Research & Development, Selling, General & Administrative expenses
Research and development (R&D) expenses increased by 7% over the prior year to NZ$42.0 million, representing 8.1% of operating revenue.
The company continued to expand its product and process research and development activities, and current new product projects include OSA masks, flow generators, humidifier systems and respiratory and acute care consumables.Selling, general and administrative (SG&A) expenses increased 1% to NZ$142.6 million, or 6% in constant currency terms, as the company continued to expand its operations and its sales teams in the North America, Europe and Asia-Pacific regions.
Outlook for FY2013
“We expect our underlying revenue growth to begin to accelerate this year, particularly in the second half, as a number of new products, including new OSA masks, are introduced around the world. We also anticipate a continuation of strong growth in demand for our products, which are used in a broad range of respiratory and surgical applications.
We expect to continue to improve constant currency operating margin, with faster growth in higher margin differentiated products, cost reductions and other efficiencies.
Exchange rates have continued to be very volatile. For the 2013 financial year, based on an exchange rate range of 0.75 to 0.80 for the NZD:USD for the remainder of the year, we expect our operating revenue to be in the range of NZ$540 million to NZ$560 million and net profit after tax to be in the range of NZ$62 million to NZ$70 million”, concluded Mr Daniell.
Source: Fisher & Paykel Healthcare